This article is more than 5 years old. Information may no longer be current.

Nightstar posts quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nightstar Therapeutics reported a net loss of $8.1 million, or $0.29 per share, in the second quarter of 2018, compared to a net loss of $4.2 million, or $0.18 per share, in last year’s second quarter.

General and administrative costs rose in the quarter from $0.7 million in 2017 to $3.3 million in 2018. According to a company press release, the increase is due to a $2 million increase in personnel-related costs and a $0.6 million increase in consulting and professional fees.

Research and development costs increased to $8.1 million in 2018’s second quarter from $3.5 million in 2017’s, which was attributed primarily to an increase in program-related expenses for the company’s rare inherited retinal disease treatment candidates NSR-REP1 for choroideremia and NSR-RPGR for X-linked retinitis pigmentosa.

The company had cash and cash equivalents of $111.4 million as of June 30, 2018.